24-week, Randomized, Double-blind, Placebo-controlled, Parallel Group Study of the Exelon [Rivastigmine] Transdermal Patch in 120 APOE e4 Positive Amnestic MCI Patients
Phase of Trial: Phase II
Latest Information Update: 02 Mar 2017
At a glance
- Drugs Rivastigmine (Primary)
- Indications Cognition disorders
- Focus Therapeutic Use
- Sponsors Cleveland Clinic
- 21 Feb 2014 Status changed from active, no longer recruiting to discontinued as reported by ClinicalTrials.gov.
- 18 Sep 2013 Status changed from recruiting to active, no longer recruiting as reported by ClinicalTrials.gov.
- 23 May 2012 New trial record